The role of kidney function on patient survival after percutaneous coronary intervention for acute coronary syndrome in left main coronary artery disease.

BACKGROUND: The prevalence of chronic kidney disease (CKD) is increasing on a global scale. Patients with CKD have a reduced quality of life and are more likely to develop significant cardiovascular disease, most commonly coronary artery disease (CAD). Left main coronary artery disease (LMCAD) is one of the most severe forms of CAD, where revascularization is needed. The aim of the study was to determine the impact of CKD on the mortality of patients after undergoing percutaneous coronary intervention (PCI) for the acute coronary syndrome (ACS) due to LMCAD. MATERIALS AND METHODS: 210 Caucasian patients (142 male; 67.6%, mean age 69.2 ± 11.3 years) with ACS due to LMCAD who underwent primary PCI were included in this retrospective study. Basic demographic and laboratory data were recorded. Patients were divided into two groups by their estimated glomerular filtration rate (eGFR). Those in the CKD group had eGFR ≤ 60 mL/min/1.73m2 (n = 82), and those in the non-CKD group had eGFR > 60 mL/min/1.73m2 (n = 128). RESULTS: The mean survival time of patients in the CKD group was 1,550 ± 1,393 days, compared to the non-CKD group of 2,149 ± 1,235 days. Kaplan-Meier survival analysis showed a statistically significant (log-rank, p < 0.0005) difference in mortality for patients in the CKD group compared to those in the non-CKD group. Cox-regression analysis showed a correlation between CKD and mortality (B = 0.541, p = 0.036), independent of arterial hypertension, diabetes mellitus, total cholesterol, and triglycerides. CONCLUSION: CKD is an independent risk factor for increased mortality after PCI due to an ACS in LMCAD.

Successful treatment of extensive uremic calciphylaxis with intravenous sodium thiosulfate and its potential in treating various diseases of pathologic calcification.

A 72-year-old female patient presented with an end-stage renal disease on on-line hemodiafiltration and warfarin therapy with advanced ulcerated calciphylaxis on the lower extremities, complicated by two episodes of cellulitis. She was successfully treated for 8 months with intravenous sodium thiosulfate in combination with modification of medication and dialysis treatment, careful wound care, and other supportive measures. Calciphylaxis is an uncommon life-threatening systemic disease, mostly occurring in patients with chronic kidney disease and other risk factors. Vascular calcifications and inflammation lead to thrombotic occlusions of the cutaneous and subcutaneous arterioles, which provoke livedoid painful plaques with possible progression to necrotic ulcers. Conventional treatment is supportive. In recent decades, off-label treatment with sodium thiosulfate, a potent calcium chelator, antioxidant, and vasodilator, has been increasingly reported to be highly efficient in calciphylaxis, leading to significantly lower mortality rates. Knowledge of advancement in the treatment of calciphylaxis, which was previously a highly fatal disease, is important for physicians and other professionals from various medical fields.

Surface Body Temperature and Thermoregulation After Cardiac Arrest.

The purpose of our study was to measure surface body temperatures (SBT) and to determine rewarming patterns after surface cooling in adult comatose survivors of cardiac arrest. We performed a prospective study in two phases from April to May 2016 and from December 2017 to March 2018. In the first phase we measured SBT as soon as possible after admission (t0) and 10 minutes later (t10). In the second phase we measured SBT and changes of SBT after local cooling of different regions in the maintenance phase of targeted temperature management. We included six patients to each phase of the study. In the first phase, we observed lower SBT compared with core body temperature (CBT) at t0 and t10, with nonsignificant differences in head and axillary region at t0 (35.2°C ± 1.3°C vs. 36°C ± 0.6°C, p = 0.11, and 35.7°C ± 1.4°C vs. 36°C ± 0.6°C, p = 0.41, respectively) and head at t10 (34.8°C ± 1.6°C vs. 35.9°C ± 0.6°C, p = 0.13). SBT in all other body regions at t0 and t10 was significantly lower compared with CBT (all p values <0.05). In the second phase, SBT was significantly lower compared with CBT in all regions (all p values <0.05). After local cooling we observed no significant differences in rewarming rate between head (2.1 ± 0.3°C/min), thorax (1.6 ± 0.4°C/min), and abdomen (1.7 ± 0.2°C/min), and a significantly faster rewarming rate when comparing other body regions with legs (0.8 ± 0.4°C/min, all p values <0.03). To conclude, in comatose survivors of cardiac arrest we discovered lower SBT compared with CBT, necessitating CBT measurements as soon as possible, and higher SBT and rewarming rates after local cooling in central (head, thorax, and abdomen) compared with peripheral (upper and lower extremities) regions of the body.

Efficacy of a bundle approach in preventing the incidence of ventilator associated pneumonia (VAP).

Ventilator-associated pneumonia (VAP) is a potentially preventable iatrogenic illness that may develop following mechanical ventilation. A bundle for the prevention of VAP consists of different measures which may vary between institutions, and may include: elevation of the head of the bed, oral care with chlorhexidine, subglottic suctioning, daily assessment for extubation and the need for proton-pump inhibitors, use of closed suction systems, and maintaining endotracheal cuff pressure at 25 cmH2O. Our aim was to determine the efficacy of a VAP prevention bundle, consisting of the above-mentioned measures, by evaluating the incidence of VAP before (no-VAP-B group) and after (VAP-B group) the introduction of the bundle. We retrospectively evaluated the data for patients who were mechanically ventilated with an endotracheal tube, in the period between 1 September and 31 December 2014 (no-VAP-B group, n = 55, 54.5% males, mean age 67.8 ± 14.5 years) and between 1 January to 30 April 2015 (VAP-B group, n = 74, 62.1% males, mean age 64.8 ± 13.7 years). There were no statistically significant differences between no-VAP-B and VAP-B groups in demographic data, intensive care unit (ICU) mortality, hospital mortality, duration of ICU treatment, and duration of mechanical ventilation. No significant differences in the rates of VAP and early VAP (onset ≤7 days after intubation) were found between no-VAP-B and VAP-B groups (41.8% versus 25.7%, p = 0.06 and 10.9% versus 12.2%, p > 0.99, respectively). However, a significant decrease in the late VAP (onset >8 days after intubation) was found in VAP-B group compared to no-VAP-B group (13.5% versus 30.9%, p = 0.027). Overall, our results support the use of VAP prevention bundle in clinical practice.